Claims
- 1. A proline derivative of the following formula (I) ##STR131## wherein: A is --O--,--NH--, ##STR132## or a single bond; B is ##STR133## W is ##STR134## or CH.sub.3 -- where R.sup.2 is a hydrogen atom, a halogen atom or a lower alkoxy;
- X is --S--, --SO--, --SO.sub.2 --, --O-- or --NH--;
- R is ##STR135## or a lower alkyl having 1 to 5 carbon atoms where 1 is an integer of 0 to 3, Y and Z are the same or different and each is a hydrogen atom, a halogen atom, a nitro, a hydroxy, a lower alkoxy or a lower alkyl having 1 to 5 carbon atoms which may be substituted by fluorine atoms, and Y and Z may combinedly form a 1,3-dioxolane ring and n is an integer of 1 to 6.
- 2. A proline derivative according to claim 1, which is selected from the group consisting of (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(phenylthio)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(phenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(phenylsulfonyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-(phenoxyacetyl)pyrrolidine, (2S)-1-[N-(4-phenylbutyryl)-L-prolyl]-2-[(phenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(4-methoxyphenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(4-nitrophenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(isopropylsulfinyl)-acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(S)-phenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(R)-phenylsulfinyl]phenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(S)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(R)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(S)-p-tolylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(R)-p-tolylsulfinyl]acetyl}pyrrolidine, (2S)-2-{[(S)-4-methoxyphenylsulfinyl]acetyl{-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-1-[N-(3-phenylpropionyl)-L-prolyl]-2-{[(S)-p-tolylsulfinyl]acetyl}pyrrolidine, (2S)-1-[N-(3-phenylpropionyl)-L-prolyl]-2-{[(S)-phenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(4-methoxyphenoxy)acetyl]pyrrolidine, (2S)-2-(phenoxyacetyl)-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-2-[(4-methoxyphenoxy)acetyl]-1-[N(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-1-(N-benzylaminocarbonyl-L-prolyl)-2-(phenoxyacetyl)pyrrolidine, (2S)-1-(N-benzylaminocarbonyl-L-prolyl)-2-(4-methoxyphenoxyacetyl)-pyrrolidine, (2S)-1-(N-benzylaminocarbonyl-L-prolyl)-2-{[(S)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine, (2S)-1-[N-(4-methoxybenzylaminocarbonyl)-L-prolyl]-2-{[(S)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine, (2S)-1-[N-(4-methoxybenzylaminocarbonyl)-L-prolyl]-2-(4-methoxyphenoxyacetyl)pyrrolidine, (2S)-2-(4-chlorophenoxyacetyl)-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-2-(4-hydroxyphenoxyacetyl)-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-1-[N-(4-chlorobenzylaminocarbonyl)-L-prolyl]-2-(4-chlorophenoxyacetyl)pyrrolidine, (2S)-1-[N-(4-fluorobenzylaminocarbonyl)-L-prolyl]-2-(4-fluorophenoxyacetyl)pyrrolidine, (2S)-1-[N-(4-chlorobenzylaminocarbonyl)-L-proline]-2-(phenoxyacetyl)pyrrolidine, (2S)-1-(N-octanoyl-L-proline)-2-(phenoxyacetyl)pyrrolidine, (2S)-1-(N-benzylaminocarbonyl)-L-proline)-2-(benzyloxyacetyl)pyrrolidine and (2S)-1-[N-(benzylaminocarbonyl)-L-prolyl]-2-{[(3,4-methylenedioxy)phenoxy]acetyl}pyrrolidine.
- 3. A pharmaceutical composition containing an effective amount of a proline derivative of the following formula (I) ##STR136## wherein: A is --O--, --NH--, ##STR137## or a single bond; B is ##STR138## W is ##STR139## or CH.sub.3 -- where R.sup.2 is a hydrogen atom, a halogen atom or a lower alkoxy;
- X is --S--, --SO--, --SO.sub.2 --, --O-- or --NH--;
- R is ##STR140## or a lower alkyl having 1 to 5 carbon atoms where 1 is an integer of 0 to 3, Y and Z are the same or different and each is a hydrogen atom, a halogen atom, a nitro, a hydroxy, a lower alkoxy or a lower alkyl having 1 to 5 carbon atoms which may be substituted by fluorine atoms, and Y and Z may combinedly form a 1,3-dioxolane ring; and
- n is an integer of 1 to 6, and a pharmaceutically acceptable diluent.
- 4. A pharmaceutical composition according to claim 3, wherein the proline derivative is selected from the group consisting of (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(phenylthio)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(phenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(phenylsulfonyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-(phenoxyacetyl)pyrrolidine, (2S)-1-[N-(4-phenylbutyryl)-L-prolyl]-2-[(phenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(4-methoxyphenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(4-nitrophenylsulfinyl)acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(isopropylsulfinyl)-acetyl]pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(S)-phenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(R)-phenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(S)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(R)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(S)-p-tolylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-{[(R)-p-tolylsulfinyl]acetyl}pyrrolidine, (2S)-2-{[(S)-4-methoxyphenylsulfinyl]acetyl}-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-1-[N-(3-phenylpropionyl)-L-prolyl)]-2-{[(S)-p-tolylsulfinyl]acetyl}pyrrolidine, (2S)-1-[N-(3-phenylpropionyl)-L-prolyl]-2-{[(S)-phenylsulfinyl]acetyl}pyrrolidine, (2S)-1-(N-benzyloxycarbonyl-L-prolyl)-2-[(4-methoxyphenoxy)acetyl]pyrrolidine, (2S)-2-(phenoxyacetyl)-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-2-[(4-methoxyphenoxy)acetyl]-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-1-(N-benzylaminocarbonyl-L-prolyl)-2-(phenoxyacetyl)pyrrolidine, (2S)-1-(N-benzylaminocarbonyl-L-prolyl)-2-(4-methoxyphenoxyacetyl)pyrrolidine, (2S)-1-(N-benzylaminocarbonyl-L-prolyl)-2-{[(S)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine, (2S)-1-[N-(4-methoxybenzylaminocarbonyl)-L-prolyl]-2-{[(S)-4-methoxyphenylsulfinyl]acetyl}pyrrolidine (2S)-1-[N-(4-methoxybenzylaminocarbonyl)-L-prolyl]-2-(4-methoxyphenoxyacetyl)pyrrolidine, (2S)-2-(4-chlorophenoxyacetyl)-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-2-(4-hydroxyphenoxyaetyl)-1-[N-(3-phenylpropionyl)-L-prolyl]pyrrolidine, (2S)-1-[N-(4-chlorobenzylaminocarbonyl)-L-prolyl]-2-(4-chlorophenoxyacetyl)pyrrolidine, (2S)-1-[N-(4-fluorobenzylaminocarbonyl)-L-prolyl]-2-(4-fluorophenoxyacetyl)pyrrolidine, (2S)-1-[N-(4-chlorobenzylaminocarbonyl)-L-proline]-2-(phenoxyacetyl)pyrrolidine, (2S)-1-(N-octanoyl-L-proline)-2-(phenoxyacetyl)pyrrolidine, (2S)-1-(N-benzylaminocarbonyl)-L-proline)-2-(benzyloxyacetyl)pyrrolidine and (2S)-1-[N-(benzylaminocarbonyl)-L-prolyl]-2-{[(3,4-methylenedioxy)phenoxy]acetyl}pyrrolidine.
Priority Claims (3)
Number |
Date |
Country |
Kind |
2-197835 |
Jul 1990 |
JPX |
|
2-418334 |
Dec 1990 |
JPX |
|
3-361355 |
Dec 1991 |
JPX |
|
Parent Case Info
This is a continuation-in-part of U.S. patent application Ser. No. 07/883,116 filed May 14, 1992, now abandoned, which is continuation-in-part of U.S. patent application Ser. No. 07/734,692 filed Jul. 23, 1991, now abandoned and a continuation-in-part of International Application No. PCT/JP92/01711 filed Dec. 25, 1992.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
4810721 |
Saitoh et al. |
Mar 1989 |
|
4857524 |
Furukawa et al. |
Aug 1989 |
|
4857537 |
Toda et al. |
Aug 1989 |
|
4880827 |
Tamoto et al. |
Nov 1989 |
|
4912128 |
Henning et al. |
Mar 1990 |
|
Foreign Referenced Citations (11)
Number |
Date |
Country |
0268190 |
May 1988 |
EPX |
0296040 |
Dec 1988 |
EPX |
0345428 |
Dec 1989 |
EPX |
60-188317 |
Sep 1985 |
JPX |
62-148467 |
Jul 1987 |
JPX |
2270557 |
Nov 1987 |
JPX |
64-42465 |
Feb 1989 |
JPX |
64-42475 |
Feb 1989 |
JPX |
1-230578 |
Sep 1989 |
JPX |
2-28149 |
Jan 1990 |
JPX |
0304085 |
Dec 1990 |
JPX |
Non-Patent Literature Citations (3)
Entry |
Patent Abstracts of Japan, vol. 11, No. 332, (C-455)(2779) Oct. 29, 1987, Abstract of Japan 62-114957(A). |
Patent Abstracts of Japan, vol. 13, No. 273, (C-609)(3621) Jun. 22, 1989, Abstract of Japan 62-225377. |
Patent Abstracts of Japan, vol. 11, NO. 332, (C-455)(2779) Oct. 29, 1987, Abstract of Japan 62-114978. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
883116 |
May 1992 |
|
Parent |
734692 |
Jul 1991 |
|